Enapotamab vedotin, an axl-specific antibody-drug conjugate, demonstrates antitumor efficacy in patient-derived xenograft models of soft tissue sarcoma

HIGHLIGHTS

• who: Britt Van Renterghem and collaborators from the Laboratory of Experimental Oncology, Catholic University of Leuven, Leuven, Belgium have published the paper: Enapotamab Vedotin, an AXL-Specific Antibody-Drug Conjugate, Demonstrates Antitumor Efficacy in Patient-Derived Xenograft Models of Soft Tissue Sarcoma, in the Journal: (JOURNAL)
• what: This study provides a preclinical rationale for the evaluation of AXL-targeting ADCs in the treatment of AXL-expressing sarcomas. The authors believe this approach has advantages over the use of selective AXL signaling inhibitors in sarcomas that are displaying complex karyotypes (>80% of STS) and are potentially . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.